The company is currently in the clinical trial stage of development, crafting their vaccine alongside Germany's BioNtech. The companies, whose project relies on messenger RNA technology never before used in an approved vaccine, dosed the first humans in Germany earlier on in May, and hope to begin a US trial soon, pending regulators' blessing. "If things go well, and the stars are aligned, we will have enough evidence of safety ...